GlaxoSmithKline Eli Lilly and Genmab-backed messenger RNA drug developer CureVac priced the offering at the top of its range.

Tencent is buying $160m of shares in the real estate platform's initial public offering, which also provides an exit for SoftBank Vision Fund.

SAIC Capital has scored an exit less than two years after it invested in the now publicly-listed intelligent manufacturing technology provider.

The Humana-backed primary care provider has closed its initial public offering after its share price more than doubled post-IPO.

The cancer treatment developer floated in the middle of its range following $175m in venture funding from investors including Novo.

The chip manufacturing services firm is set to go public $268m in an oversubscribed offering that will enable Samsung, Xiaomi and Intel to exit.

The Softbank, Telstra and American Express-backed e-commerce software producer has closed its IPO after its shares more than tripled in price.

The number of corporate-backed companies going public declined in 2019, despite some major IPOs like those of Uber, Lyft and Slack.

Gene therapy developer Freeline Therapeutics priced an upsized offering at the top of its range following $275m in funding from investors including Novo.

UCL's Freeline Therapeutics has priced its shares at $18 to raise nearly $159m through an IPO on the Nasdaq Global Select Market.